HomeInsightsStock Comparison

Medicamen Biotech Ltd vs Megasoft Ltd Stock Comparison

Medicamen Biotech Ltd vs Megasoft Ltd Stock Comparison

Last Updated on: Jul 18, 2025

Key Highlights

  • The Latest Trading Price of Medicamen Biotech Ltd is ₹ 406.7 as of 18 Jul 10:42.
  • The P/E Ratio of Medicamen Biotech Ltd changed from 16.6 on March 2020 to 44.5 on March 2024 . This represents a CAGR of 21.80% over 5 yearsThe P/E Ratio of Megasoft Ltd changed from 31.4 on March 2020 to 0 on March 2024 . This represents a CAGR of -100.00% over 5 years.
  • The Market Cap of Medicamen Biotech Ltd changed from ₹ 220.75 crore on March 2020 to ₹ 487.1 crore on March 2024 . This represents a CAGR of 17.15% over 5 yearsThe Market Cap of Megasoft Ltd changed from ₹ 22.27 crore on March 2020 to ₹ 659.06 crore on March 2024 . This represents a CAGR of 96.90% over 5 years.
  • The revenue of Medicamen Biotech Ltd for the Mar '25 is ₹ 34.84 crore as compare to the Dec '24 revenue of ₹ 45.28 crore. This represent the decline of -23.06% The revenue of Megasoft Ltd for the Mar '25 is ₹ 12.66 crore as compare to the Dec '24 revenue of ₹ 12.73 crore. This represent the decline of -0.55%.
  • The ebitda of Medicamen Biotech Ltd for the Mar '25 is ₹ 3.62 crore as compare to the Dec '24 ebitda of ₹ 6.85 crore. This represent the decline of -47.15% The ebitda of Megasoft Ltd for the Mar '25 is ₹ 9.52 crore as compare to the Dec '24 ebitda of ₹ 9.4 crore. This represent the growth of 1.28%.
  • The net profit of Medicamen Biotech Ltd changed from ₹ 3.95 crore to ₹ 1.86 crore over 8 quarters. This represents a CAGR of -31.38% The net profit of Megasoft Ltd changed from ₹ 3.25 crore to ₹ 3.44 crore over 8 quarters. This represents a CAGR of 2.88% .
  • The Dividend Payout of Medicamen Biotech Ltd changed from 4.98 % on March 2020 to 9.56 % on March 2024 . This represents a CAGR of 13.93% over 5 yearsThe Dividend Payout of Megasoft Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Medicamen Biotech Ltd

  • A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
  • The Company has presence in 40+ countries.
  • Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
  • MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
  • The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

About Megasoft Ltd

  • Megasoft Limited is a transnational intellectual property-driven, product-based technology company, which incorporated on 29th June 1999 and focused its expertise on the telecom sector.
  • The Company provides telecom services throughout the globe under XIUS-bcgi and also offers Outsourcing, Off-shoring and back-office services to other product companies in the areas of Product Life Cycle Management (PLM) & and Application Development & Maintenance Services (ADMS) under the name and style of BlueAlly.
  • Megasoft has strong product engineering and product development capacities with Capability Maturity Model (CMM) Level 5 certification and has operations in India, U.S., UK, Singapore, Malaysia and Germany. The Company had merged with Indus e solutions a public listed company in the year of 2000.

Medicamen Biotech Ltd News Hub

News

Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection

The ANDA pertains to Bortezomib for Injection, 3.5 mg single-dose vial. The USFDA has dete...

Read more

03 Jun 2025 13:07

News

Board of Medicamen Biotech recommends final dividend

Medicamen Biotech announced that the Board of Directors of the Company at its meeting held...

Read more

31 May 2025 12:29

News

Medicamen Biotech to hold board meeting

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 30 May 2...

Read more

23 May 2025 20:27

News

Medicamen Biotech to convene EGM

Medicamen Biotech announced that an Extra Ordinary General Meeting (EGM) of the Company wi...

Read more

27 Feb 2025 16:47

News

Medicamen Biotech announces board meeting date

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 26 Febru...

Read more

21 Feb 2025 19:50

News

Medicamen Biotech to declare Quarterly Results

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 11 Febru...

Read more

05 Feb 2025 14:45

Megasoft Ltd News Hub

News

Megasoft revises board meeting date

Megasoft has revised the meeting of the Board of Directors which was scheduled to be held ...

Read more

22 May 2025 11:13

News

Megasoft to announce Quarterly Result

Megasoft will hold a meeting of the Board of Directors of the Company on 23 May 2025. Powe...

Read more

20 May 2025 17:22

News

Megasoft to hold board meeting

Megasoft will hold a meeting of the Board of Directors of the Company on 14 February 2025....

Read more

11 Feb 2025 11:19

News

Megasoft schedules board meeting

Megasoft will hold a meeting of the Board of Directors of the Company on 11 November 2024 ...

Read more

07 Nov 2024 14:15

News

Megasoft to conduct AGM

Megasoft announced that the Annual General Meeting (AGM) of the company will be held on 27...

Read more

06 Sep 2024 16:38

News

Megasoft schedules AGM

Megasoft announced that the Annual General Meeting (AGM) of the company will be held on 27...

Read more

06 Sep 2024 17:41

SWOT Analysis Of Medicamen Biotech Ltd

Strength

4

S

Weakness

0

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Megasoft Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Medicamen Biotech Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Megasoft Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Medicamen Biotech Ltd and Megasoft Ltd

Which company has a larger market capitalization, Medicamen Biotech Ltd or Megasoft Ltd?

Market cap of Medicamen Biotech Ltd is 559 Cr while Market cap of Megasoft Ltd is 782 Cr

What are the key factors driving the stock performance of Medicamen Biotech Ltd and Megasoft Ltd?

The stock performance of Medicamen Biotech Ltd and Megasoft Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Biotech Ltd and Megasoft Ltd?

As of July 18, 2025, the Medicamen Biotech Ltd stock price is INR ₹412.45. On the other hand, Megasoft Ltd stock price is INR ₹106.05.

How do dividend payouts of Medicamen Biotech Ltd and Megasoft Ltd compare?

To compare the dividend payouts of Medicamen Biotech Ltd and Megasoft Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions